Adult GlioblastomaPhase 1NCT04573140Papers
Autologous total tumor mRNA
RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
Chronic CED of TPT for Recurrent Malignant Glioma
What the film says
Some brain tumors announce themselves fast. Others take their time. An IDH-mutant glioma is the patient one.
It begins with a typo. IDH is an enzyme in the cell's energy cycle, and in more than seven out of ten lower-grade gliomas, one letter of its gene is wrong. The altered enzyme makes a chemical the body has no use for, and that chemical jams the machinery a cell uses to read its own genes. The tumor that follows grows slowly. It tends to arrive in people in their thirties. And after surgery, radiation and chemotherapy, it comes back. Nearly always, and often more aggressive than before.
When it does come back, there is no standard treatment.
Here is the frustrating part. Drugs that kill these cells in a dish already exist. Topotecan is one. Given by vein, it failed completely in recurrent glioblastoma: in one study, none of twenty-eight patients responded. The drug was not the problem. Getting it to the tumor was.
The brain protects itself. Blood vessels in the brain are sealed shut with tight junctions, and pumps in their walls push foreign molecules back out. It is a good wall, and it cannot tell a poison from a treatment. Raise the dose in the bloodstream enough to force the wall and you poison the rest of the body first.
So what if you skipped the bloodstream?
That is convection-enhanced delivery. A surgeon places a fine catheter into the tumor and the brain around it, and a pump pushes the drug in under gentle pressure. Not diffusion, which fades within millimeters, but bulk flow, which carries a drug centimeters through tissue. Add a contrast agent to the mix and an MRI scan will show you exactly where the drug went.
One more detail shapes the whole design. Topotecan only kills a cell that is actively copying its DNA, and at any moment only a few tumor cells are. A short infusion misses the rest. But the early versions of this ran a tube out through the scalp to a pump at the bedside, and after about four days the risk of infection ends the treatment.
The fix was to put the pump inside the body. A programmable pump, the kind already implanted to deliver pain medicine to the spine, sits under the skin of the chest, is refilled through a needle, and can run as long as it is needed.
In twenty twenty-two, a team at Columbia published the first five patients treated this way. Four infusions of forty-eight hours each, over about a month, with patients at home in between. No severe side effects were blamed on the drug. When the treated tissue was examined afterwards, the share of dividing tumor cells had fallen from roughly four percent to one and a half, and the drug was found as far as six centimeters from the catheter. All five patients eventually died of their disease, and the authors were careful to say that five patients cannot prove benefit.
That study treated a different subtype. This trial brings the method to IDH-mutant tumors for the first time. Six adults whose glioma has returned, at Columbia University in New York, led by Jeffrey Bruce, who has spent a career on this problem. Two operations, four infusions, and one question first. Is it safe?
Everything in this film comes from the published record, and it is not medical advice.
Sources behind this film
Yan H. N Engl J Med, 2009
IDH is an enzyme in the cell's energy cycle; one wrong letter in more than seven out of ten lower-grade gliomas; Grows slowly; tends to arrive in people in their thirties
Han S. Br J Cancer, 2020
The altered enzyme makes a chemical the body has no use for that jams how a cell reads its genes; Comes back nearly always, often more aggressive
Grows slowly; tends to arrive in people in their thirties; Comes back nearly always, often more aggressive; Topotecan by vein failed: none of twenty-eight patients responded; Raise the intravenous dose and you poison the body first (+3 more lines)
No standard treatment when it returns
Friedman HS. Cancer, 1999
Topotecan by vein failed: none of twenty-eight patients responded
Bhowmik A. Biomed Res Int, 2015
The brain's vessels are sealed with tight junctions and pumps push drugs back out
Shen J. Cancer Res, 2009
The brain's vessels are sealed with tight junctions and pumps push drugs back out
Bobo RH. Proc Natl Acad Sci U S A, 1994
Convection-enhanced delivery: gentle pressure, bulk flow, centimeters not millimeters
Spinazzi EF. Lancet Oncol, 2022
A contrast agent shows on MRI where the drug went; Topotecan only kills cells actively copying DNA, so a short infusion misses the rest; Early versions ran a tube through the scalp and had to stop after about four days; Five patients; four 48-hour infusions over about a month; at home in between (+5 more lines)
Bruce JN. Neurosurgery, 2011
Early versions ran a tube through the scalp and had to stop after about four days
Sonabend AM. Neuro Oncol, 2011
An implanted programmable pump, like those used for spinal pain medicine, refilled through a needle
The drug
Topotecan (TPT) is a chemotherapeutic agent that is a topoisomerase inhibitor. This intervention is uniquely distinguished through its administration using an externalized catheter and external microinfusion pump (Convection-Enhanced Delivery)
Malignant gliomas are among the most pernicious of human tumors. They are locally invasive and universally recurrent, often recurring within two centimeters of the original resection cavity.
Although numerous chemotherapeutic drugs demonstrate significant anti-tumor activity in preclinical studies, their efficacy in clinical trials has been dismal; systemic delivery fails to achieve therapeutic drug levels in tumor cells due to various factors including limited blood-brain barrier permeability and systemic toxicity.
The study
The primary goal of this study is to establish the safety of chronic Convection Enhanced Delivery (CED) of the chemotherapeutic drug Topotecan for patients with recurrent malignant glioma that harbors the Isocitrate Dehydrogenase mutation (IDH-mut). The secondary goal of the study is to study drug distribution and assess the tumor response to prolonged continuous CED of Topotecan.
Convection Enhanced Delivery is a novel method of drug delivery that allows administration of a drug directly to the brain. In CED, a drug pump is placed under the skin in the chest or abdominal region. The pump is connected to a catheter that is tunneled underneath the skin to the brain. The tip of the catheter then infuses Topotecan directly onto the brain tumor.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.